BLU-667: New Hope for NSCLC and Medullary Thyroid Cancer

Share this post

RET mutations and rearrangements have been identified across several solid tumors, including non-small cell lung cancer (NSCLC), and for the first time, a new potent inhibitor shows activity in humans.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply